 Cerebellar Neoplasms
"Cerebellar Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)
| Descriptor ID |
D002528
|
| MeSH Number(s) |
C04.588.614.250.195.411.211 C10.228.140.211.500.200 C10.228.140.252.200 C10.551.240.250.400.300
|
| Concept/Terms |
Cerebellar Neoplasms- Cerebellar Neoplasms
- Cerebellar Tumors
- Cerebellar Tumor
- Tumor, Cerebellar
- Neoplasms, Cerebellar
- Cerebellar Neoplasm
- Neoplasm, Cerebellar
Cerebellar Neoplasms, Primary- Cerebellar Neoplasms, Primary
- Cerebellar Neoplasm, Primary
- Primary Cerebellar Neoplasm
- Primary Cerebellar Neoplasms
- Primary Neoplasms, Cerebellum
- Cerebellum Primary Neoplasm
- Cerebellum Primary Neoplasms
- Neoplasm, Cerebellum Primary
- Primary Neoplasm, Cerebellum
- Neoplasms, Cerebellar, Primary
Benign Cerebellar Neoplasms- Benign Cerebellar Neoplasms
- Benign Cerebellar Neoplasm
- Cerebellar Neoplasm, Benign
- Neoplasm, Benign Cerebellar
- Neoplasms, Cerebellar, Benign
- Cerebellar Neoplasms, Benign
Cerebellar Cancer- Cerebellar Cancer
- Cancer, Cerebellar
- Cerebellar Cancers
- Cerebellar Neoplasms, Malignant
- Neoplasms, Cerebellar, Malignant
- Malignant Cerebellar Neoplasms
- Cerebellar Neoplasm, Malignant
- Malignant Cerebellar Neoplasm
- Neoplasm, Malignant Cerebellar
|
Below are MeSH descriptors whose meaning is more general than "Cerebellar Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Cerebellar Neoplasms".
This graph shows the total number of publications written about "Cerebellar Neoplasms" by people in this website by year, and whether "Cerebellar Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 2007 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2012 | 8 | 0 | 8 | | 2013 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 4 | 0 | 4 | | 2021 | 6 | 0 | 6 | | 2022 | 6 | 0 | 6 | | 2023 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Cerebellar Neoplasms" by people in Profiles.
-
Wolin AR, Vincent MY, Hotz T, Purdy SC, Rosenbaum SR, Hughes CJ, Hsu JY, Oliphant MUJ, Armstrong B, Wessells V, Varella-Garcia M, Galbraith MD, Pierce A, Wang D, Venkataraman S, Danis E, Veo B, Serkova N, Espinosa JM, Gustafson DL, Vibhakar R, Ford HL. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression. Neuro Oncol. 2023 12 08; 25(12):2287-2301.
-
Okonechnikov K, Joshi P, Sepp M, Leiss K, Sarropoulos I, Murat F, Sill M, Beck P, Chan KC, Korshunov A, Sah F, Deng MY, Sturm D, DeSisto J, Donson AM, Foreman NK, Green AL, Robinson G, Orr BA, Gao Q, Darrow E, Hadley JL, Northcott PA, Gojo J, Kawauchi D, Hovestadt V, Filbin MG, von Deimling A, Zuckermann M, Pajtler KW, Kool M, Jones DTW, J?ger N, Kutscher LM, Kaessmann H, Pfister SM. Mapping pediatric brain tumors to their origins in the developing cerebellum. Neuro Oncol. 2023 10 03; 25(10):1895-1909.
-
Shishido K, Purvis IJ, Velpula KK, Venkataraman S, Vibhakar R, Asuthkar S. Targeting B7-H3 through EZH2 inhibition in MYC-positive Group 3 medulloblastoma. Oncol Rep. 2023 Jun; 49(6).
-
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Bl?mel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, W?lfl M, Milde T, Witt O, Erdreich-Epstein A, Leprivier G, Kahlert U, Stefanski A, St?hler K, Keir ST, Bigner DD, Hauer J, Beez T, Knobbe-Thomsen CB, Fischer U, Felsberg J, Hansen FK, Vibhakar R, Venkatraman S, Cheshier SH, Reifenberger G, Borkhardt A, Kurz T, Remke M, Mitra S. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. J Immunother Cancer. 2023 01; 11(1).
-
Cooney T, Lindsay H, Leary S, Wechsler-Reya R. Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group. Neoplasia. 2023 01; 35:100861.
-
Hendrikse LD, Haldipur P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudi?re-Morrison L, Mercier AL, Shokouhian M, Su?rez RA, Ly M, Borlase S, Scott DS, Vladoiu MC, Farooq H, Sirbu O, Nakashima T, Nambu S, Funakoshi Y, Bahcheli A, Diaz-Mejia JJ, Golser J, Bach K, Phuong-Bao T, Skowron P, Wang EY, Kumar SA, Balin P, Visvanathan A, Lee JJY, Ayoub R, Chen X, Chen X, Mungall KL, Luu B, B?rub? P, Wang YC, Pfister SM, Kim SK, Delattre O, Bourdeaut F, Doz F, Masliah-Planchon J, Grajkowska WA, Loukides J, Dirks P, F?vre-Montange M, Jouvet A, French PJ, Kros JM, Zitterbart K, Bailey SD, Eberhart CG, Rao AAN, Giannini C, Olson JM, Garami M, Hauser P, Phillips JJ, Ra YS, de Torres C, Mora J, Li KKW, Ng HK, Poon WS, Pollack IF, L?pez-Aguilar E, Gillespie GY, Van Meter TE, Shofuda T, Vibhakar R, Thompson RC, Cooper MK, Rubin JB, Kumabe T, Jung S, Lach B, Iolascon A, Ferrucci V, de Antonellis P, Zollo M, Cinalli G, Robinson S, Stearns DS, Van Meir EG, Porrati P, Finocchiaro G, Massimino M, Carlotti CG, Faria CC, Roussel MF, Boop F, Chan JA, Aldinger KA, Razavi F, Silvestri E, McLendon RE, Thompson EM, Ansari M, Garre ML, Chico F, Egu?a P, P?rezpe?a M, Morrissy AS, Cavalli FMG, Wu X, Daniels C, Rich JN, Jones SJM, Moore RA, Marra MA, Huang X, Reimand J, Sorensen PH, Wechsler-Reya RJ, Weiss WA, Pugh TJ, Garzia L, Kleinman CL, Stein LD, Jabado N, Malkin D, Ayrault O, Golden JA, Ellison DW, Doble B, Ramaswamy V, Werbowetski-Ogilvie TE, Suzuki H, Millen KJ, Taylor MD. Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022 09; 609(7929):1021-1028.
-
Wang D, Veo B, Pierce A, Fosmire S, Madhavan K, Balakrishnan I, Donson A, Alimova I, Sullivan KD, Joshi M, Erlander M, Ridinger M, Foreman NK, Venkataraman S, Vibhakar R. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy. Neuro Oncol. 2022 03 12; 24(3):414-426.
-
Hart M, Anderson-Mellies A, Beltrami A, Gilani A, Green AL. Population-based analysis of CNS tumor diagnoses, treatment, and survival in congenital and infant age groups. J Neurooncol. 2022 Apr; 157(2):333-344.
-
Riemondy KA, Venkataraman S, Willard N, Nellan A, Sanford B, Griesinger AM, Amani V, Mitra S, Hankinson TC, Handler MH, Sill M, Ocasio J, Weir SJ, Malawsky DS, Gershon TR, Garancher A, Wechsler-Reya RJ, Hesselberth JR, Foreman NK, Donson AM, Vibhakar R. Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma. Neuro Oncol. 2022 02 01; 24(2):273-286.
-
Peng J, Kim DD, Patel JB, Zeng X, Huang J, Chang K, Xun X, Zhang C, Sollee J, Wu J, Dalal DJ, Feng X, Zhou H, Zhu C, Zou B, Jin K, Wen PY, Boxerman JL, Warren KE, Poussaint TY, States LJ, Kalpathy-Cramer J, Yang L, Huang RY, Bai HX. Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors. Neuro Oncol. 2022 02 01; 24(2):289-299.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|